A randomized phase 2 clinical trial to treat moderate-to-severe plaque psoriasis patients with high-induction dosing of risankizumab
- Journal:
- Nature Communications
- Published:
- Affiliations:
- 3
- Authors:
- 12
| Institutions | Authors | Share |
|---|---|---|
| University of Michigan (U-M), United States of America (USA) | 0.58 | |
| Oregon Medical Research Center (OMRC), United States of America (USA) | 0.25 | |
| AbbVie, United States of America (USA) | 0.17 |